New strategy to resume and taper epoprostenol after lung transplant for pulmonary hypertension.
Akihiro OhsumiAkihiro AoyamaHideyuki KinoshitaTomoya YonedaKazuhiro YamazakiSatona TanakaDaisuke NakajimaTadashi IkedaKenji MinatoyaHiroshi DatePublished in: General thoracic and cardiovascular surgery (2022)
To resume and taper epoprostenol administration after reperfusion in patients with severe PH may be a valuable new strategy associated with better perioperative outcomes.
Keyphrases
- pulmonary hypertension
- patients undergoing
- cardiac surgery
- acute myocardial infarction
- pulmonary artery
- early onset
- cerebral ischemia
- pulmonary arterial hypertension
- acute ischemic stroke
- heart failure
- type diabetes
- acute coronary syndrome
- acute kidney injury
- adipose tissue
- coronary artery disease
- weight loss
- glycemic control